Compare DAC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | OGN |
|---|---|---|
| Founded | 1972 | 1923 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2006 | 2020 |
| Metric | DAC | OGN |
|---|---|---|
| Price | $114.40 | $6.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $105.00 | $11.75 |
| AVG Volume (30 Days) | 72.7K | ★ 4.3M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 3.04% | 1.11% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.65 |
| P/E Ratio | ★ $4.01 | $10.01 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $65.40 | $6.18 |
| 52 Week High | $118.83 | $15.88 |
| Indicator | DAC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 36.26 |
| Support Level | $91.64 | $6.48 |
| Resistance Level | N/A | $7.74 |
| Average True Range (ATR) | 2.93 | 0.37 |
| MACD | 0.75 | -0.08 |
| Stochastic Oscillator | 72.33 | 22.41 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.